TRYP-0082

DRUG2 trials

Sponsors

TRYP Therapeutics

Conditions

Binge Eating DisorderIrritable Bowel Syndrome

Phase 2

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

CompletedNCT05035927

TRYP TherapeuticsBinge Eating Disorder

Start: 2022-03-16End: 2024-06-07Updated: 2024-11-19

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

Active, not recruitingNCT06206265

TRYP TherapeuticsIrritable Bowel Syndrome

Start: 2024-01-17End: 2026-03-01Updated: 2026-02-05